• In February 2026, Tempus AI, Inc. reported full-year 2025 results showing sales of US$955.38 million, revenue of US$1.27 billion, and a net loss of US$245.03 million, alongside new 2026 revenue guidance of about US$1.59 billion and the launch of its HRD-RNA oncology algorithm, while also filing a US$343.38 million Class A common stock shelf registration tied to an ESOP offering.
• These updates suggest Tempus AI is pairing rapid top-line expansion and narrowing losses with advancing AI-driven cancer diagnostics and data partnerships that could influence its long-term business profile.
• We’ll now examine how Tempus AI’s stronger 2025 results and higher 2026 revenue outlook may influence its existing investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Tempus AI Investment Narrative Recap

To own Tempus AI, you need to believe its genomics and AI platform can eventually convert strong revenue growth into a viable, less cash‑hungry business, despite ongoing losses. The latest results and 2026 guidance highlight improving scale but do not fundamentally change the near term tension between rapid investment and the key risk that reimbursement, margins, and data demand may not keep pace with the company’s spending needs.

The launch of the HRD‑RNA oncology algorithm is especially relevant here, because it showcases how Tempus AI is trying to turn its data and AI capabilities into differentiated cancer diagnostics. If HRD‑RNA and similar products gain research and then clinical traction, they could support the company’s push toward higher value tests and AI insights, which ties directly into the short term catalysts around revenue mix and perceived competitive positioning.

Yet even with this progress, investors should be aware that intensifying competition and uncertain reimbursement for new AI‑driven assays could still...

Tempus AI's narrative projects $2.1 billion revenue and $295.0 million earnings by 2028.

Uncover how Tempus AI's forecasts yield a $86.71 fair value, a 63% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$2.5 billion by 2029, but if AI‑based “dry lab” services fail to gain meaningful reimbursement, those expectations and the newer HRD‑RNA catalyst may look very different, so it is worth comparing your own view to these more aggressive scenarios.

Explore 18 other fair value estimates on Tempus AI - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.